BIO News and Press, Bio-Rad Laboratories Inc. Class A From 02/16/23

Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Edward Chung - Vice President, Investor Relations Ilan Daskal - Chief Financial Officer Andrew Last - Chief Operating Officer Norman Schwartz - Presi...

Bio-Rad Labs press release ( NYSE: BIO ): Q4 Non-GAAP EPS of $3.31. Revenue of $730.3M (-0.3% Y/Y). For FY 2023, co anticipates non-GAAP, currency-neutral revenue growth of approximately 6.0% to 7.0% and an estimated non-GAAP operating margin of approximately 19.5%. For ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 perc...

Summary Qiagen is seeing a pandemic-driven hangover in its financial results, but underlying double-digit revenue growth was ahead of expectations. The pandemic meaningfully accelerated system placements for its sample prep, diagnostics, and PCR businesses, and now management can shift ...

Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits PR Newswire SAN DIEGO and HERCULES, Calif. , ...

Summary MSC's controlling Class B shareholders have brought a proposal to exchange their shares for Class A shares at a 35% premium, eliminating the dual-class share structure. MSC's Class B shareholders, generally members of the founding Jacobson family, including the current CEO, cont...

FREMONT, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products ...

Summary Charles River Laboratories has proven itself to be a quality player in its space. Shares of the company don't look all that cheap, but they aren't exactly expensive either. When paired with the consistency of its growth and the robust cash flows of the firm, it becomes a dec...

Summary Waters Corporation has been a source of relative stability over the past several months, with the company performing slightly better than the broader market. This comes as sales rise but also while profits and cash flows come under some pressure. If shares were cheaper, the ...

Summary Bruker offers a range of advantages over peers: profitability, value, growth, and more. As such, the company is well-positioned to provide strong returns in the future. This article will address recent developments, highlight the advantages, and discuss the opportunity. ...